“Revolutionary” anti-obesity drugs like Ozempic appear to be the right tool to deal with the addictive, highly processed foods that are ruining Americans’ health, former FDA Commissioner David Kessler writes at the New York Times . He says GLP-1 drugs helped him end the “cycle of despair” of weight loss and…
What You Should Know: – A new study from Mayo Clinic, released this past weekend, signals a significant advancement in understanding and potentially mitigating the challenging side effects associated with popular GLP-1 agonist medications like Wegovy and Zepbound. – Led by Mayo Clinic physician and obesity expert Andres Acosta, MD, PhD, the research reveals that … Read more
Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan B, DiMarchi RD, Sloop KW, Samms RJ, Theis FJ, Tschöp MH, Müller TD. GIPR agonism and antagonism decrease body weight … Read more
For all the dramatic effects of the GLP-1 agonists (and now the GLP-1/GIPR ligands as a combination), there are still a lot of mysteries around how they work. Two new papers (published simultaneously) are helping to reveal some of what’s going on, and I very much suspect that we will have more surprises to uncover. … Read more
Professor of Medicine Joel Habener. Veasey Conway/Harvard Staff Photographer Health How just a fishing expedition helped lead to GLP-1 Story of game-changing therapy illustrates crucial role of fundamental research breakthroughs Jacob Sweet Harvard Staff Writer May 8, 2025 4 min read Part of the Profiles of Progress series Sometimes an important discovery springs from a … Read more
BALTIMORE–(BUSINESS WIRE)—- $TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of … Read more
BOSTON–(BUSINESS WIRE)–OM1: What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1’s Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite … Read more
January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large, international study across multiple sites in six countries, it compared GLP1-RA users with those using dipeptidyl peptidase-4 inhibitors (DPP-4is), another class … Read more
Abstract Aim Type 2 diabetes mellitus (T2DM) is associated with an increased risk of delirium and mortality. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide metabolic and neuroprotective benefits, their long-term impact on delirium risk remains uncertain. This study compares GLP-1 RAs and metformin in relation to delirium and mortality in T2DM patients using real-world … Read more
by Carol A Westbrook What is the hardest thing about dieting, the reason that most dieters give up? They get hungry. Wouldn’t it be great if there were a pill that would leave you satisfied after a diet meal without those hunger pangs? A medicine that would keep you on a diet and help you … Read more